跳至主要内容
临床试验/NCT01156259
NCT01156259Unknown3 期

Phase 3 Study of 30Gy Versus 40Gy Involved-field Radiotherapy in Localized Diffuse Large B Cell Lymphoma Achieving CR After Chemotherapy

Chinese Academy of Medical Sciences1 个研究点 分布在 1 个国家目标入组 400 人开始时间: 2010年4月最近更新:
适应症

试验速览

阶段
3 期
入组人数
400
试验地点
1
主要终点
disease free survival

研究概览

简要总结

The purpose of this study is to determine whether 30Gy Involved-field Radiotherapy (IFRT) is as effective as 40Gy in the treatment of localized Diffused Large B cell Lymphoma (DLBCL) when completing CR after chemotherapy.

详细描述

The best proper doses of IFRT in combined modality treatments (CMT) for localized DLBCL is still undetermined. Existing treatment guidelines recommend 40Gy or above as the standard treatment dosage. However, there were large-scaled clinical trials implying smaller doses such as 30Gy may be equivalent effective. Lowering radiation doses can decrease treatment toxicities and radiotherapy-induced diseases, which has been conformed by HD13 study for Hodgkin's Lymphoma. It may even retain the truth when modern era radiation techniques are involved and especially in patients achieving CR after chemotherapy. A comprehensive, prospective dose-comparing study is needed.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
15 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • biopsy-proved Diffuse Large B cell lymphoma
  • nonbulky stage I, nonbulky stage IE, nonbulky stage II, or nonbulky stage IIE disease(Bulky disease was defined as a mass 10 cm or more in maximal diameter) according to Ann Arbor Staging
  • provide written informed consent
  • Complete regression after chemotherapy
  • Considerable to CT simulation and 3D CRT or IMRT
  • Performance status 0-2 WHO criteria;life expectation>6 months
  • negative for human immunodeficiency virus syndrome (HIV)
  • Minimal staging included chest radiograph, computed tomography of the abdomen and pelvis, and single percutaneous bone marrow biopsy and blood studies

排除标准

  • primary mediastinal large B cell lymphoma
  • dermatological lymphoma
  • testicular lymphoma
  • primary central nerve system lymphoma
  • history of low-grade lymphoma congestive
  • history of heart failure (CHF; New York Heart Association [NYHA] classifications III-IV), history of neoplasm (adequately treated basal cell carcinoma of the skin or in situ carcinoma of the uterine cervix were allowed), abnormal liver function tests (aminotransferases and alkaline phosphatase > 2.5 times the upper limit of normal, bilirubin > 50 ), renal insufficiency (serum creatinine > 300 ), and patients with any serious medical or psychiatric illness that would prevent informed consent or completion of protocol-prescribed treatment and follow-up

结局指标

主要结局

disease free survival

时间窗: five years

次要结局

  • overall survival(five years)
  • acute treatment toxicity(up to 16 weeks)
  • late treatment toxicity(five years)
  • treatment failure type(five years)

研究者

申办方类型
Other

研究点 (1)

Loading locations...

相似试验